Corcept Therapeutics

YTD

ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.

CEO

Joseph K. Belanoff

CEOJoseph K. Belanoff

Employees

730

Employees730

Headquarters

Redwood City, California

HeadquartersRedwood City, California

Founded

1998

Founded1998

Employees

730

Employees730

CORT Key Statistics

Market cap

7.56B

Market cap7.56B

Price-Earnings ratio

198.54

Price-Earnings ratio198.54

Dividend yield

—

Dividend yield—

Average volume

1.03M

Average volume1.03M

High today

$71.12

High today$71.12

Low today

$68.25

Low today$68.25

Open price

$69.29

Open price$69.29

Volume

1.08M

Volume1.08M

52 Week high

$91.00

52 Week high$91.00

52 Week low

$28.66

52 Week low$28.66

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $70.44, giving the company a market capitalization of 7.56B. It carries a P/E multiple of 198.54.

On 2026-06-01, Corcept Therapeutics(CORT) stock moved within a range of $68.25 to $71.12. With shares now at $70.44, the stock is trading +3.2% above its intraday low and -0.9% below the session's peak.

Trading volume for Corcept Therapeutics(CORT) stock has reached 1.08M, versus its average volume of 1.03M.

The stock's 52-week range extends from a low of $28.66 to a high of $91.00.

CORT News

Simply Wall St 2d

Corcept Therapeutics Is Up 15.4% After Positive Lifyorli Phase 3 Ovarian Cancer Survival Data – Has The Bull Case Changed? - simplywall.st

...

TipRanks 3d

Top Corcept Executive Makes Notable Move With Fresh Stock Sale

New insider activity at Corcept Therapeutics ( (CORT) ) has taken place on May 29, 2026. Unlock trusted, data-backed investing tools with TipRanks Premium, fro...

Simply Wall St 4d

A Look At Corcept Therapeutics Valuation As Relacorilant NDA Resubmission Advances Toward FDA Decision

Corcept Therapeutics (CORT) has put relacorilant for Cushing’s syndrome back in front of the FDA, planning to resubmit its New Drug Application after additional...

Analyst ratings

83%

of 6 ratings

Buy

83.3%

Hold

16.7%

Sell

More CORT News

TipRanks 4d

Corcept stockholders approve expanded incentive plan and board

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

TipRanks 4d

Corcept Therapeutics price target raised to $135 from $110 at Canaccord

Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $135 from $110 and keeps a Buy rating on the shares. The firm Corcept surprised today...

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Novo Nordisk

Broadcom

Robinhood Markets

Palantir Technologies

Spotify

Gilead Sciences

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.